Business Wire

Innodisk and Microsoft Announce Strategic Alliance, Pushing for New Out-of-Band Standard for Secure AIoT Device Management

Share

Innodisk is hosting media and industry partners at an exclusive Taipei event with a focus on establishing a new standard of AIoT storage and device management. Joining Innodisk’s president Randy Chien is Microsoft’s APAC GM of IoT Device Experience, Shirley Strachan, who together will announce the two companies’ strategic partnership. The event will also be attended by some of the main actors in the industry, SuperMicro, DFI, Avalue, and IEI, who will be showcasing how their products can integrate Innodisk and Microsoft’s new solution.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191120006043/en/

Innodisk is announcing the strategic partnership with Microsoft and push out of band management to AIoT edge devices. (Photo: Business Wire)

Innodisk is announcing the strategic partnership with Microsoft and push out of band management to AIoT edge devices. (Photo: Business Wire)

World’s First SSD with Integrated Azure Sphere
With the new InnoAGE™ SSD with Microsoft’s MCU, Azure Sphere, Innodisk introduces an innovative flash device with independent Out-of-Band connectivity. The compact Microsoft MCU ensures connection to the cloud and comes with extensive security measures to protect user data and access. Innodisk’s hardware and firmware expertise further strengthen security at the edge with encryption and versatile data erasure options.

The Main Obstacle to IoT Deployment
On an average basis, IoT system integrators have to chip in an additional 80% of upfront costs for subsequent maintenance and management after having installed digital infrastructure. This significant sum is largely due to downtime and its derived costs. IoT devices can be managed and monitored remotely, but once they crash, the only option left is sending someone out to physically fix and recover the system, ultimately leading to higher maintenance costs and increased downtime.

Solving the Maintenance Predicament
Out-of-Band connection tackles this issue by adding a separate pathway to access the system. The InnoAGE SSD connects via standard in-band solutions, but also offers out-of-band connectivity through Ethernet or WiFi. This means that the SSD is fully able to run system recovery if the OS is inaccessible or the whole system crashes, offering a quick and simple way to get devices up and running without relying on physical access.

Expanding AIoT Markets
The InnoAGE SSD aims at the emerging smart markets within established fields such as medical facilities, factories, transportation, and surveillance. Randy Chien, the president of Innodisk states: “We are constantly looking for avenues to actualize AIoT, which is why we at Innodisk are working together with partners to realize AI at the edge. Microsoft is an important partner when we face down one of the greatest challenges of IoT implementation, namely efficient device management and cutting downtime.”

About Innodisk
Featured on Forbes’ Asia’s 200 Best Under A Billion companies, Innodisk is a service-driven provider of flash memory, DRAM modules and embedded peripheral products for the industrial and enterprise applications. With satisfied customers across the embedded, aerospace and defense, cloud storage markets and more, we have set ourselves apart with a commitment to provide customizable, dependable solutions and unparalleled service.

For more information about Innodisk, please visit https://www.innodisk.com

Contact information

Innodisk Corporation
Benjamin Jokela, +886 277033000 ext. 1516
Benjamin_Jokela@innodisk.com
Yvonne Liu, +886 277033000 ext. 1515
Yvonne_Liu@innodisk.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta Treatment7.12.2019 22:00:00 EETPress release

Kite, a Gilead Company (Nasdaq: GILD), today announced new data from the ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma. These results included updated overall survival data from the pivotal phase 2 study after three years following a single infusion of Yescarta, as well as an analysis from a separate safety management cohort of patients receiving early steroid intervention for cytokine release syndrome (CRS) and neurologic events. The data were presented today at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, in Orlando from December 7–10, 2019. With a minimum follow-up of three years after a single infusion of Yescarta (median follow-up of 39.1 months), approximately half (n=47/101; 47 percent) of patients with refractory large B-cell lymphoma in ZUMA-1 pivotal phase 2 cohorts were alive, and the median overall survival (OS) was 25.8 months. These updated three-year survival data were presented a

Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma7.12.2019 18:20:00 EETPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today initial results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-68284528 (JNJ-4528), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy being evaluated in the treatment of patients with relapsed or refractory multiple myeloma. The study enrolled patients who had received at least three prior lines of therapy or were double refractory to a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD); had received a PI, IMiD and an anti-CD38 antibody. The CARTITUDE-1 study results, premiered at the American Society of Hematology (ASH) Annual Meeting, were featured as an oral presentation and highlighted in the official ASH press programme (Abstract #577).1 Results from the Phase 1b portion of the CARTITUDE-1 study showed early and deep responses among patients (n=29) with a median of five prior multiple myeloma

Imbruvica®▼(ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukaemia7.12.2019 18:18:00 EETPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced combination data from two studies and a long-term integrated analysis evaluating the use of Imbruvica® (ibrutinib) for the treatment of previously untreated patients with CLL. Results from a 48-month follow-up analysis of the Phase 3 E1912 clinical study reported a statistically significant difference in PFS and OS for ibrutinib plus rituximab compared to a standard chemoimmunotherapy regimen of FCR.1 Further, the latest integrated analysis from the Phase 3 RESONATETM (PCYC-1112) and RESONATETM-2 (PCYC-1115/1116) studies investigating the use of single-agent ibrutinib in CLL, reported at up to six years of follow-up, PFS, OS and response rates improved when ibrutinib was used in earlier lines of therapy.2 During this extended follow-up, ibrutinib was tolerated across all lines of therapy with 19 percent of patients discontinuing due to adverse events.2 In addition, results presented from the Phase 2 CAPTIVATE stu

Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis7.12.2019 17:30:00 EETPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the 61st American Society of Hematology (ASH) annual meeting on Saturday, December 7, 2019 in Orlando, Florida. TOURMALINE-AL1 is a Phase 3, randomized clinical trial evaluating the effect of NINLAROTM (ixazomib) in combination with dexamethasone in patients with relapsed or refractory systemic light-chain (AL) amyloidosis. The TOURMALINE-AL1 trial did not meet the first of the two primary endpoints of significant improvement in overall hematologic response, as reported in June 2019. Hematologic responses were seen in 53% versus 51% of patients receiving NINLARO plus dexamethasone versus physician’s choice (odds ratio 1.10 [95% CI 0.60-2.01], p=0.762) as assessed by an Adjudication Committee (AC). The second primary endpoint of two-year vital organ deterioration or death was not mature at the time of analysis. Other endpoints stu

Schlumberger Announces Fourth-Quarter and Full-Year 2019 Results Conference Call6.12.2019 21:07:00 EETPress release

Schlumberger Limited (NYSE:SLB) will hold a conference call on January 17, 2020 to discuss the results for the fourth quarter and full year ending December 31, 2019. The conference call is scheduled to begin at 8:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (844) 721-7241 within North America or +1 (409) 207-6955 outside of North America approximately 10 minutes prior to the start of the call and the access code is 4013483. A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until February 17, 2020, and can be accessed by dialing +1 (866) 207-1041 within North Amer

BUFF STUDIO Globally Launches My Coloring, a Mobile 3D Pixel Art Coloring Book Game6.12.2019 16:00:00 EETPress release

BUFF STUDIO announced on December 5 that it launched My Coloring, a mobile 3D pixel art coloring book game, in 155 countries simultaneously. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191206005162/en/ BUFF STUDIO launched My Coloring, a mobile 3D pixel art coloring book game, in 155 countries simultaneously. My Coloring is a game that materializes a 3D pixel art coloring book on mobile devices. You can blow your stress away as you paint spaces in the order of numbers on the screen while reading calming messages. Relaxing background music you will listen during gameplay and its fairytale-like design will give you pleasure and happiness. You can download it for free on Google Play and the Apple App Store. (Graphic: Business Wire) Its Android and iOS versions were released at the same time so the users can download it for free on Google Play and the Apple App Store. My Coloring is a game that materializes a 3D pixel art col

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom